Literature DB >> 28438796

Critical Need for Clarity in Polymyxin B Dosing.

Nikolas J Onufrak1, Gauri G Rao1, Alan Forrest1, Jason M Pogue2, Marc H Scheetz3,4, Roger L Nation5, Jian Li6, Keith S Kaye7.   

Abstract

Keywords:  pharmacodynamics; pharmacokinetics; polymyxin B

Mesh：

Substances：

Year:  2017        PMID： 28438796      PMCID： PMC5404569          DOI： 10.1128/AAC.00208-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods.

Authors:  Brian C Nelson; Daniel P Eiras; Angela Gomez-Simmonds; Angela S Loo; Michael J Satlin; Stephen G Jenkins; Susan Whittier; David P Calfee; E Yoko Furuya; Christine J Kubin
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

2.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Authors:  Ana M Sandri; Cornelia B Landersdorfer; Jovan Jacob; Márcio M Boniatti; Micheline G Dalarosa; Diego R Falci; Tainá F Behle; Rosaura C Bordinhão; Jiping Wang; Alan Forrest; Roger L Nation; Jian Li; Alexandre P Zavascki
Journal:  Clin Infect Dis       Date:  2013-05-22       Impact factor: 9.079

3.  Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report.

Authors:  Andrea L H Kwa; Kamilia Abdelraouf; Jenny G H Low; Vincent H Tam
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

4.  Comparative Pharmacokinetic Profiling of Different Polymyxin B Components.

Authors:  Pooja Manchandani; Yanina Dubrovskaya; Song Gao; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

Review 5.  Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application.

Authors:  S Vozeh; J L Steimer
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

6.  Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency.

Authors:  Visanu Thamlikitkul; Yanina Dubrovskaya; Pooja Manchandani; Thundon Ngamprasertchai; Adhiratha Boonyasiri; Jessica T Babic; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

7.  Adaptive control of theophylline therapy: importance of blood sampling times.

Authors:  D Z D'Argenio; K Khakmahd
Journal:  J Pharmacokinet Biopharm       Date:  1983-10

8.  Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.

Authors:  Maria Helena Rigatto; Tainá F Behle; Diego R Falci; Thiela Freitas; Natane T Lopes; Mariá Nunes; Leonardo W Costa; Alexandre P Zavascki
Journal:  J Antimicrob Chemother       Date:  2015-01-20       Impact factor: 5.790

9.  Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections.

Authors:  Andrea L H Kwa; Tze-Peng Lim; Jenny G H Low; JingGuo Hou; Asok Kurup; Randall A Prince; Vincent H Tam
Journal:  Diagn Microbiol Infect Dis       Date:  2007-10-04       Impact factor: 2.803

10.  Pharmacokinetics of intravenous polymyxin B in critically ill patients.

Authors:  Alexandre P Zavascki; Luciano Z Goldani; Guoying Cao; Silvana V Superti; Larissa Lutz; Afonso L Barth; Fabiano Ramos; Márcio M Boniatti; Roger L Nation; Jian Li
Journal:  Clin Infect Dis       Date:  2008-11-15       Impact factor: 9.079
View more
  6 in total

1.  Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients.

Authors:  Cristina Miglis; Nathaniel J Rhodes; Sean N Avedissian; Christine J Kubin; Michael T Yin; Brian C Nelson; Manjunath P Pai; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

2.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251

Review 3.  Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.

Authors:  Daniel Gonzalez; Gauri G Rao; Stacy C Bailey; Kim L R Brouwer; Yanguang Cao; Daniel J Crona; Angela D M Kashuba; Craig R Lee; Kathryn Morbitzer; J Herbert Patterson; Tim Wiltshire; Jon Easter; Scott W Savage; J Robert Powell
Journal:  Clin Transl Sci       Date:  2017-08-10       Impact factor: 4.689

4.  Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections-A Cohort Study.

Authors:  Yiying Cai; Hui Leck; Ray W Tan; Jocelyn Q Teo; Tze-Peng Lim; Winnie Lee; Maciej Piotr Chlebicki; Andrea L Kwa
Journal:  Antibiotics (Basel)       Date:  2020-07-27

Review 5.  A Review of the Clinical Pharmacokinetics of Polymyxin B.

Authors:  Sean N Avedissian; Jiajun Liu; Nathaniel J Rhodes; Andrew Lee; Gwendolyn M Pais; Alan R Hauser; Marc H Scheetz
Journal:  Antibiotics (Basel)       Date:  2019-03-22

6.  Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety.

Authors:  Jian Qu; Ting-Ting Qi; Qiang Qu; Wen-Ming Long; Ying Chen; Yue Luo; Ying Wang
Journal:  Infect Drug Resist       Date:  2022-03-22       Impact factor: 4.003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.